Product Information
LYUMJEV 100 UNIT/ML VIAL is a brand product labeled by Eli Lilly and Company, priced at $7.8733 per ML under NDC 00002772801. Its NADAC has been published 255 times since Nov 17, 2021.
Strength
100 [iU]/mL
Manufacturer
Eli Lilly and CompanyNDC
00002772801
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
INSULIN LISPROApproval Type
Biologic (BLA)
FDA Application
BLA761109On Market Since
6/15/2020
Pharmacological Classes
Price Statistics
The NADAC for LYUMJEV 100 UNIT/ML VIAL has been published 255 times since Nov 17, 2021, and over the history we have for it it has declined 70.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.8733 per ML |
|---|---|
| All-time high | $26.4247 (Apr 10, 2024) |
| All-time low | $7.8733 (Sep 23, 2026) |
| 52-week high | $26.3143 |
| 52-week low | $7.8733 |
| Median price | $26.3298 |
| Average price | $23.7103 |
| Largest weekly change | -70.0% (Jan 28, 2026) |
| Weeks tracked | 255 |
| Tracking since | Nov 17, 2021 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Insulin lispro-aabc market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LYUMJEV 100 UNIT/ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for LYUMJEV 100 UNIT/ML VIAL, manufactured by Eli Lilly and Company, is $7.8733 per ML (NDC 00002772801), effective Sep 30, 2026.
How has the price of LYUMJEV 100 UNIT/ML VIAL changed over time?
Over the history we have for it, the NADAC for LYUMJEV 100 UNIT/ML VIAL has declined 70.1%. It has been tracked across 255 weekly CMS publications since Nov 17, 2021.
What are the highest and lowest recorded NADAC prices for LYUMJEV 100 UNIT/ML VIAL?
Since Nov 17, 2021, the NADAC for LYUMJEV 100 UNIT/ML VIAL has ranged from a low of $7.8733 (Sep 23, 2026) to a high of $26.4247 (Apr 10, 2024), with a median of $26.3298 per ML.
Are there cheaper alternatives to LYUMJEV 100 UNIT/ML VIAL?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as LYUMJEV 100 UNIT/ML VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures LYUMJEV 100 UNIT/ML VIAL?
LYUMJEV 100 UNIT/ML VIAL (NDC 00002772801) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.